CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer

Nobuyuki Yamamoto,Haruyasu Murakami,Hidetoshi Hayashi,Yasuhito Fujisaka,Tomonori Hirashima,Koji Takeda,Miyako Satouchi,K. Miyoshi,S. Akinaga,Toshiaki Takahashi,K. Nakagawa

CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer

2013

Nobuyuki Yamamoto
Haruyasu Murakami
Hidetoshi Hayashi
Yasuhito Fujisaka
Tomonori Hirashima
Koji Takeda
Miyako Satouchi
K. Miyoshi
S. Akinaga
Toshiaki Takahashi
K. Nakagawa

CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer

Keywords:

c-Met inhibitor
Medicine
Drug Dosage Calculation
Erlotinib
Cell
Pathology
Tivantinib
Cancer research
Lung cancer
Genotype
CYP2C19
Erlotinib Hydrochloride
Neutropenia
Rash
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations